First safety test for liver drug in damaged livers
NCT ID NCT05045482
Summary
This study aims to understand how a drug called Saroglitazar is processed by the body in people with liver damage caused by a specific type of liver disease. It will compare 30 participants with mild, moderate, or severe liver damage to people with normal liver function. The main goal is to check the drug's safety and see how it moves through the body at different doses over 28 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zydus US002
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.